Drug-induced immune thrombocytopenic purpura secondary to sunitinib

Sunitinib (Sutent: Pfizer, New York, NY, U.S.A.) is an oral multi-targeted tyrosine kinase inhibitor approved for use in various solid tumour malignancies. Many side effects secondary to sunitinib have been documented. In particular, sunitinib administration is known to result in thrombocytopenia, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Trinkaus, M., Trudeau, M., Callum, J.
Formato: Texto
Lenguaje:English
Publicado: Multimed Inc. 2008
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442762/
https://www.ncbi.nlm.nih.gov/pubmed/18596889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442762/
https://www.ncbi.nlm.nih.gov/pubmed/18596889

Ejemplares similares